Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
Anna ZabalzaGeorgina ArrambidePaula TaglianiSimón Cárdenas-RobledoSusana Otero-RomeroJuliana EsperalbaCandela Fernandez-NavalJesus Trocoli CampuzanoMónica Martinez-GalloMireia CastilloMercè BonastreMireia Resina SallésJordina BeltranPere Carbonell-MirabentMarta Rodríguez-BarrancoSamuel López-MazaPedro José Melgarejo OtáloraMariano Ruiz-OrtizAgustín PappollaBreogan Rodriguez AcevedoLuciana MidagliaÁngela Vidal-JordanaÁlvaro Cobo-CalvoCarmen TurIngrid GalánJoaquín CastillóJordi RíoCarmen EspejoManuel Comabella LopezCarlos NosJaume Sastre-GarrigaMar TintoreXavier MontalbanPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti-CD20-treated patients, even in the absence of antibodies.